S&P Futures
4,162.50 -29.00 (-0.69%) Dow Futures
34,028.00 -69.00 (-0.20%) Nasdaq Futures
12,677.00 -169.75 (-1.32%) Russell 2000 Futures
2,007.20 -0.70 (-0.03%) Crude Oil
75.83 -0.05 (-0.07%) Gold
1,925.80 -5.00 (-0.26%)
Intellia Therapeutics, Inc. (NTLA)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 43.15 |
| Open | 44.47 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's Range | 43.45 - 46.03 |
| 52 Week Range | 32.44 - 104.87 |
| Volume | |
| Avg. Volume | 1,219,588 |
| Market Cap | 3.319B |
| Beta (5Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.40 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 116.72 |
- TheStreet.com
Does Intellia Therapeutics Stock Have Good Genes?
CRISPR editing firm Intellia Therapeutics was rated a new fundamental "overweight" (buy) by a sell-side firm Wednesday with a $67 price target. The On-Balance-Volume (OBV) line has been weak with a low just made in January. The weekly OBV line has struggled the past 18 months or so but may have made a low in January.
- InvestorPlace
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks
- InvestorPlace
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr
